SBIO 股价预测及 ETF 分析 - 分红·管理费·持仓·NAV·RSI·MACD | 美股今日
AI 绘制的图表形态仅供参考。
详细指标表
| Category | US Equities - Industry Sector | Expense | 0.5% | Return% 1Y | 30.11% | Total Holdings | 104 | Perf Week | 5.9% | Volume | 28,977 |
| Asset Type | Equities (Stocks) | AUM | $193M | Return% 3Y | 33.58% | NAV | $57.55 | Perf Month | 6.93% | Avg Volume | 0.04M |
| ETF Type | US Equities | Dividend TTM | - | Return% 5Y | 4.7% | 52W High | -18.73% | Perf Quarter | -15.04% | Rel Volume | 0.77 |
| Active/Passive | Passive | Div Gr. 3/5Y | - | Return% 10Y | 10.91% | 52W Low | 30.72% | Perf Half Y | 4.43% | Prev Close | $57.60 |
| IPO | 2014/12/31 | Flows% 1M | -3.42% | Return% SI | 8.1% | RSI (14) | 55.67 | Perf YTD | 12.42% | Price | $57.58 |
| Beta | 0.78 | Flows% 3M | 4.96% | Flows% YTD | 41.8% | Flows% 1Y | 83.49% | Perf Year | 29.57% | Volatility(W/M) | 4.07% 3.24% |
| SMA20 | 5.98% | SMA50 | -0.65% | SMA200 | 0.75% | ATR | 1.85 | ||||
ALPS Medical Breakthroughs ETF seeks investment results that correspond (before fees and expenses) generally to the performance of its underlying index, the S-Network Medical Breakthroughs Index. The fund employs a "passive management" - or indexing - investment approach designed to track the performance of the underlying index. It will normally invest at least 80% of its net assets in securities that comprise the underlying index. The underlying index is comprised of small and mid-cap stocks of biotechnology companies that have one or more drugs in either Phase II or Phase III of the U.S. Food and Drug Administration clinical trials.
前10大持仓占 基金的31%
按持仓比重从大到小。
过去1年中, 处于中等水平
较一年最高价低 19%。
成交量低于平时。 相当于平均成交量的77%。
若长期持有, 跑赢大盘
如果5年前买入,现在的收益率是+24.0%。 同期标普500为+62%。
点击查看数字
价格 波动较大
最糟糕时(2021年2月)下跌了63%,用了972天才恢复。
点击查看数字
没有股息
目前还没有可分配的利润。
资金持续流入
最近一年流入了相当于资产83.5%的新资金。
点击查看数字